Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8

As key regulators of epigenetic regulation, human histone deacetylases (HDACs) have been identified as drug targets for the treatment of several cancers. The proper recognition of zinc-binding groups (ZBGs) will help improve the accuracy of virtual screening for novel HDAC inhibitors. Here, we developed a high-specificity ZBG-based pharmacophore model for HDAC8 inhibitors by incorporating customized ZBG features. Subsequently, pharmacophore-based virtual screening led to the discovery of three novel HDAC8 inhibitors with low micromole IC50 values (1.8-1.9 μM). Further studies demonstrated that compound H8-A5 was selective for HDAC8 over HDAC 1/4 and showed antiproliferation activity in MDA-MB-231 cancer cells. Molecular docking and molecular dynamic studies suggested a possible binding mode for H8-A5, which provides a good starting point for the development of HDAC8 inhibitors in cancer treatment.

[1]  K. Foon,et al.  A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study , 2014, Leukemia & lymphoma.

[2]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[3]  Youyong Li,et al.  Discovery of novel inhibitors targeting the macrophage migration inhibitory factor via structure-based virtual screening and bioassays. , 2014, Journal of medicinal chemistry.

[4]  O. Wiest,et al.  Zinc binding in HDAC inhibitors: a DFT study. , 2007, The Journal of organic chemistry.

[5]  P. McCarren,et al.  The Chemical Tuning of a Weak Zinc Binding Motif for Histone Deacetylase Using Electronic Effects , 2012, Chemical biology & drug design.

[6]  M. Mrksich,et al.  3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition. , 2013, Journal of medicinal chemistry.

[7]  Evgenia V. Dueva,et al.  Inhibitors of tick-borne flavivirus reproduction from structure-based virtual screening. , 2013, ACS medicinal chemistry letters.

[8]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[9]  L. Klaman,et al.  Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms , 2005, Molecular Pharmacology.

[10]  Yong-Jun Jiang,et al.  Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. , 2008, Journal of molecular graphics & modelling.

[11]  Nicolas Moitessier,et al.  Docking Ligands into Flexible and Solvated Macromolecules. 6. Development and Application to the Docking of HDACs and other Zinc Metalloenzymes Inhibitors , 2014, J. Chem. Inf. Model..

[12]  S. Altamura,et al.  Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. , 2009, Journal of medicinal chemistry.

[13]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Rowley,et al.  Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[15]  Jian Zhang,et al.  How to Improve Docking Accuracy of AutoDock4.2: A Case Study Using Different Electrostatic Potentials , 2013, J. Chem. Inf. Model..

[16]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[17]  C. Fierke,et al.  Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . , 2010, Biochemistry.

[18]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[19]  Tingjun Hou,et al.  Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility , 2014, J. Chem. Inf. Model..

[20]  Yu Cao,et al.  Virtual screening in small molecule discovery for epigenetic targets. , 2015, Methods.

[21]  Patrisha Joseph Therese,et al.  Multiple e-Pharmacophore Modeling, 3D-QSAR, and High-Throughput Virtual Screening of Hepatitis C Virus NS5B Polymerase Inhibitors , 2014, J. Chem. Inf. Model..

[22]  Xun Li,et al.  Interpretation of the Binding Affinities of PTP1B Inhibitors with the MM-GB/SA Method and the X-Score Scoring Function , 2009, J. Chem. Inf. Model..

[23]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[25]  Ruibo Wu,et al.  Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study. , 2010, Journal of chemical theory and computation.

[26]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[27]  M. K. Pflum,et al.  Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.

[28]  Yong Eun Kim,et al.  A Structure‐Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc‐Chelating Groups , 2010, ChemMedChem.

[29]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[30]  Xuben Hou,et al.  Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. , 2014, Journal of medicinal chemistry.

[31]  Yan-tao Han,et al.  Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy , 2015, Medicinal research reviews.

[32]  Arthur J. Olson,et al.  AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins , 2014, J. Chem. Inf. Model..

[33]  Yong-Jun Jiang,et al.  3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. , 2009, European journal of medicinal chemistry.

[34]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[35]  Takayoshi Suzuki,et al.  Thermodynamics of Binding of Structurally Similar Ligands to Histone Deacetylase 8 Sheds Light on Challenges in the Rational Design of Potent and Isozyme-Selective Inhibitors of the Enzyme , 2014, Biochemistry.

[36]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[37]  Hao Tang,et al.  Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation , 2009, J. Chem. Inf. Model..

[38]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[39]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[40]  M. Binaschi,et al.  Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.

[41]  O. Wiest,et al.  Inhibition and Mechanism of HDAC8 Revisited , 2014, Journal of the American Chemical Society.

[42]  Zhon-Yin Zhang,et al.  Small molecule tools for functional interrogation of protein tyrosine phosphatases , 2013, The FEBS journal.

[43]  M. Lübbert,et al.  Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.

[44]  Gisbert Schneider,et al.  Significance estimation for sequence-based chemical similarity searching (PhAST) and application to AuroraA kinase inhibitors. , 2012, Future medicinal chemistry.

[45]  V. Castronovo,et al.  Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. , 2004, The American journal of pathology.

[46]  Ø. Bruserud,et al.  Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. , 2007, Current pharmaceutical biotechnology.

[47]  Ajay N. Jain,et al.  Surflex-Dock: Docking benchmarks and real-world application , 2012, Journal of Computer-Aided Molecular Design.

[48]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[49]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[50]  Ø. Bruserud,et al.  Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells , 2007 .

[51]  Vincent Zoete,et al.  Toward On-The-Fly Quantum Mechanical/Molecular Mechanical (QM/MM) Docking: Development and Benchmark of a Scoring Function , 2014, J. Chem. Inf. Model..

[52]  P. Soden,et al.  Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit. , 2013, Journal of medicinal chemistry.

[53]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[54]  J. Bradner,et al.  On the inhibition of histone deacetylase 8. , 2010, Bioorganic & medicinal chemistry.

[55]  M. Mrksich,et al.  Synthesis and Structure−Activity Relationship of 3‐Hydroxypyridine- 2-thione-Based Histone Deacetylase Inhibitors , 2013 .

[56]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[57]  Andrew R. Leach,et al.  A Comparison of Field‐Based Similarity Searching Methods: CatShape, FBSS, and ROCS. , 2008 .

[58]  Yixue Li,et al.  Regulation of Cellular Metabolism by Protein Lysine Acetylation , 2010, Science.

[59]  A. Anderson,et al.  Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. , 2013, ACS medicinal chemistry letters.

[60]  Lenwood S. Heath,et al.  H++: a server for estimating pKas and adding missing hydrogens to macromolecules , 2005, Nucleic Acids Res..

[61]  S. Sakkiah,et al.  Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. , 2010, European journal of medicinal chemistry.

[62]  Ruibo Wu,et al.  Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. , 2011, Journal of the American Chemical Society.

[63]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[64]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[65]  K. Bechtol,et al.  Chunaram Choudhary Major Cellular Functions Lysine Acetylation Targets Protein Complexes and Co-Regulates , 2012 .

[66]  K. Garber.  HDAC inhibitors overcome first hurdle , 2007, Nature Biotechnology.

[67]  Naresh Kandakatla,et al.  Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors , 2014, Adv. Bioinformatics.

[68]  R. De Francesco,et al.  Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex , 2007, EMBO reports.

[69]  Ruibo Wu,et al.  A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. , 2010, Journal of the American Chemical Society.

[70]  Seth M. Cohen,et al.  Investigating the selectivity of metalloenzyme inhibitors. , 2013, Journal of medicinal chemistry.

[71]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[72]  Giulia Russo,et al.  Discovery of a novel small molecule inhibitor targeting the frataxin/ubiquitin interaction via structure-based virtual screening and bioassays. , 2013, Journal of medicinal chemistry.

[73]  Stefano Alcaro,et al.  Identification and characterization of new DNA G-quadruplex binders selected by a combination of ligand and structure-based virtual screening approaches. , 2013, Journal of medicinal chemistry.

[74]  Terry P Lybrand,et al.  Staggered Mesh Ewald: An extension of the Smooth Particle-Mesh Ewald method adding great versatility. , 2009, Journal of chemical theory and computation.

[75]  M. K. Pflum,et al.  Mutagenesis Studies of the 14 Å Internal Cavity of Histone Deacetylase 1: Insights toward the Acetate-Escape Hypothesis and Selective Inhibitor Design , 2014, Journal of medicinal chemistry.

[76]  O. Wiest,et al.  Computational exploration of zinc binding groups for HDAC inhibition. , 2013, The Journal of organic chemistry.

[77]  H. Fang,et al.  Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. , 2011, Journal of medicinal chemistry.

[78]  Berk Hess,et al.  P-LINCS:  A Parallel Linear Constraint Solver for Molecular Simulation. , 2008, Journal of chemical theory and computation.

[79]  P. Coveney,et al.  Loop Interactions and Dynamics Tune the Enzymatic Activity of the Human Histone Deacetylase 8 , 2013, Journal of the American Chemical Society.

[80]  P. Geerlings,et al.  DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[81]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[82]  C. Fierke,et al.  Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. , 2008, Biochemistry.

[83]  E. Seto,et al.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.

[84]  Lin-Li Li,et al.  ID-Score: A New Empirical Scoring Function Based on a Comprehensive Set of Descriptors Related to Protein-Ligand Interactions , 2013, J. Chem. Inf. Model..

[85]  P. Atadja,et al.  Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. , 2011, Bioorganic & medicinal chemistry.

[86]  Adriano Martinelli,et al.  Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities , 2009, J. Chem. Inf. Model..